avx701
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2007 (NCT00529984)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Carcinoembryonic antigen-related cell adhesion molecule 5Immunity, active
CEACAM5 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- avx701
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01890213 | Phase 1 | Nov 1, 2013 | AlphaVax, Inc., Duke University |
| NCT00529984 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2007 | AlphaVax, Inc., Duke University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AlphaVax, Inc. | For profit | 2 | 1 | 2 | 2007 |
| Duke University | Academic/Hospital | 2 | 1 | 2 | 2007 |
2 organizations
Page 1 / 1